Aim: To make an accurate estimation of the association of ERCC1 and ERCC2 polymorphisms with osteosarcoma (OS) prognosis in Chinese population. Conclusion: This study did not support rs11615, rs13181 or rs1799793 to be used as surrogate markers for clinical outcome of osteosarcoma with chemotherapy.
Introduction
Osteosarcoma (OS) is the most common primary bone malignancy which is approximately 19% of all bone tumors. Treatments usually combine aggressive standard-of-care surgical techniques and alkylating agent-based chemotherapy regimens, as improved survival was reported in combined chemotherapy compared to surgical only treatment. [1] However, sarcomas are usually diagnosed at an advanced stage, most primary therapeutic modalities including surgery, chemotherapy and biological therapies are not particularly effective. As one of the lowest survival rates among various cancers, although the 5-year survivorship of OS patients is 70% with localized disease, the survival rate drops to 30% for metastatic cases. [2] [3] [4] And significant differences were observed on the treatment effect even from patients received same therapeutic modalities. [5] Hence, it is of great clinical significance to explore the underlying mechanisms of disease development and progression.
Excision repair cross-complementation group 1 (ERCC1) and excision repair cross-complementation group 2 (ERCC2) are important enzymes in nucleotide excision repair (NER) pathway responsible for restoring cisplatin-induced DNA damages, such as intrastrand and interstrand crosslinks (ICLs). Germline polymorphisms in DNA damage repair genes, such as ERCC1 and ERCC2, could have an important impact on both survival rates and chemotherapy treatment-related toxicity. [6] Therefore, the identification of predictive markers could lead to improved drug selection and treatment outcomes. [7, 8] However, the published results from previous studies on the association of ERCC1 and ERCC2 polymorphism with prognosis in chemotherapy-treated osteosarcoma in China were inconsistent. For example, some studies showed that ERCC1 rs11615 is associated with OS survival treatment with cisplatin, [9] and the ERCC1 rs11615CC genotype had a longer overall survival compared with the TT genotype. [10] While there are also results suggested that the ERCC1 rs11615 TT genotype and ERCC2 rs1799793 AA genotype were associated with longer overall survival when compared with those with the wild-type Neoadjuvant chemotherapy based on doxorubicin, methotrexate, cisplatin and ifosfamide before and after surgery. EFS = event-free survival, OS = overall survival.
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Medicine genotype. [11] The conclusions on ERCC2 polymorphism were also inconsistent. Some studies suggested no association between ERCC2 rs13181 polymorphisms and overall survival in patients with osteosarcoma under cisplatin-based chemotherapy. [12] [13] [14] However, a recent meta-analysis found that the ERCC2 rs13181 polymorphisms might influence osteosarcoma prognosis.
[15] Thus, we performed a meta-analysis based on the most updated qualified studies trying to make an accurate estimation of such association in Chinese population.
Methods
This study was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements. All data were extracted from previous studies, and no direct patient contact or influence on patient care was involved in this research. Thus, ethical approval and informed patient consent were not required.
Search strategy and data collection
Literature search was carried out by 2 investigators (Dabiao Liu and Xuesong Liu) independently from the PubMed (1966-2015), Embase (1980 Embase ( -2015 and the Web of Science (1945-2015) using the search term based on a combination of Medical Subject Headings (MeSH) and text words relating to "ERCC1", "ERCC2", " osteosarcoma", and "chemotherapy". Dabiao Liu reviewed the literature and extract the data. Possible review author's bias, however, might exist due to limited literature resources.
The retrieved literature (up to November 11, 2015) was further screened based on the following criteria for inclusion in our analysis: ERCC1 and ERCC2 genetic polymorphisms and overall survival (OS), event-free survival (EFS), progression-free survival (PFS) and 5 years survival rate, the event at the end of follow-up time in osteosarcoma patients' treatment with chemotherapy in Chinese population. During this screening process, all included studies were also evaluated in terms of the selection bias in the clinical trials. All participants recruited in the related studies were randomly selected to allow random sequence generation. The 
Medicine groups, if applicable, were all randomly assigned without foreknowledge of the forthcoming allocations. Performance and detection bias was also reduced in all included studies by performing effective blinding during the monitoring period in the clinical trials. Both groups described in the included studies received similar treatment and interventions. Possible reporting bias might exist in those studies which might slightly affect the results from individual studies. Exclusion criteria were the following:
(1) other treatment method such as surgery and radiotherapy; (2) the study population is not Chinese; (3) duplicates, review articles.
We collected the data of outcomes from all qualified studies for the construction of a 2 Â 2 (dichotomous data) table, to assess the relationship between SNP of ERCC1 and ERCC2 and the prognosis in osteosarcoma patient from chemotherapy. All randomized controlled trials included in the manuscript were evaluated to meet the quality assurance of the meta-analysis based on the quality of reports of meta-analyses (QUORUM) guidelines.
Statistical methods
Forest plots were constructed using STATA 12 software (STATA Corp LP, College Station, Texas, United States). Where appropriate, odds ratios (ORs) with 95% CIs were pooled for the survival rate in different osteosarcoma patients with ERCC1 and ERCC2 genetic polymorphisms. The heterogeneity of results across the studies was assessed using the I 2 test. If statistical heterogeneity was small (I 2 < 50%) a Mantel-Haenszel fixed-effects model was used. For studies with moderate statistical heterogeneity (I 2 > 50%), the D-L random-effect model was applied. Potential publication bias of the datasets used in our analysis was assessed by Begg funnel plot and Egger linear regression test.
Result

Study description
Total 42 articles were retrieved from first round search, of which 35 studies were excluded after a careful review. Seven qualified studies with 1404 OS patients were included in this metaanalysis. The selection process and the reasons for exclusion were illustrated in Figure 1 . The characteristics of included studies were summarized in Table 1 . Possible bias might exist in the included studies, however, full evaluations were performed on each included studies.
ERCC1 rs11615 SNP and prognosis of chemotherapy in OS patient
Total of 1284 OS patients from 6 studies were pooled to investigate the relationship between rs11615 and prognosis of chemotherapy. The D-L random-effect model was applied due to the obvious between-study heterogeneity (P < .10 and I 2 > 50% under all models). We did not find significant association under either dominant [TT+TC vs Table 2 , Fig. 2A ). Begg funnel plots and Egger test were used to assessing the potential publication bias in included studies under all model. Begg funnel com plot did not show asymmetry for all 3 models with P > .05 (Fig. 2B-D , Table 2 ). However, the P value of Egger linear regression test reveals evidence of obvious asymmetry ( Table 2 , P < .05).
Relation between response rate and ERCC2 SNP in OS patient
Seven studies were pooled to investigate the relationship between rs13181 and prognosis of chemotherapy with a total of 1398 OS patients. As no between-study heterogeneity was observed (P > .10 and I 2 < 50% under all genetic models), the fix-effect model was used for all genetic models. Fig. 3A) . Begg funnel plots did not show asymmetry for all 3 models with P > .05 (Fig. 3B-D , Table 2 ). The P values of the Egger test were greater than .05 for the recessive and allelic model; while P = .012 in dominant model ( Table 2) .
The relationship between rs1799793 and prognosis of chemotherapy was analyzed with a total of 1215 OS patients from 6 studies. Due to the obvious between-study heterogeneity (P > .10 and I 2 < 50% under all genetic models), the fix-effect model was used for all genetic models. As shown in Figure 4A Table 2 ). All the Begg funnel plots under 3 models were symmetrical and P values of Egger test were all greater than .05 (Fig. 4B-D, Table 2 ).
Discussion
Currently, the multidisciplinary approach for osteosarcoma patients follows a neoadjuvant therapy, including 4 drugs: high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide, followed by surgery. [16] Studies showed that the outcome of neoadjuvant chemotherapy varies for patients with tumors show >90% necrosis vs whose tumors do not respond to the chemotherapy. [17] The identification and validation of surrogate biomarkers are of great clinical significance for personalized therapy and patients' quality of life in osteosarcoma treatment regimen. For those patients unlikely to respond to the alkylating agent-based chemotherapy, alternative therapy should be offered.
In the present meta-analysis, with the most updated sample size from 7 qualified studies of 1404 OS patients in the Chinese population, we tried to validate some ERCC1 and ERCC2 prognostic biomarkers for osteosarcoma after chemotherapy. Under all models tested, contrary to previous publications, our results could not find prominent association between 3 ERCC1 and ERCC2 polymorphisms (rs11614, rs13181, and rs1799793) and prognosis of OS patient treated with chemotherapy in the Chinese population. The discrepancy of our results from previous studies may be caused by different study design, tumor types and most likely the sample size. Our result suggested that rs11615, rs13181, and rs1799793 could not be used as surrogate markers for clinical outcome of osteosarcoma treatment with chemotherapy.
Similar to all other meta-analysis, our study might have some limitations. First of all, different source data may generate heterogeneity in the current meta-analysis. For example, moderate-high heterogeneity was detected by the I 2 test in some data sets. Secondly, publication bias might be an issue. In this study, we used a funnel plot for the detection of potential publication bias or heterogeneity and further evaluated by Egger linear test. For some model, although no asymmetry was observed, but the P values of Egger are smaller than .05, suggesting publication bias might not be excluded. More studies should be included in the future to further confirm our result.
In conclusion, rs11615, rs13181, and rs1799793 are not prognostic markers for osteosarcoma patients. The developing of validated clinical prognostic biomarkers and treatments based on the individual molecular profile instead of general chemotherapy will open new avenues for osteosarcoma patient care.
